Article

Cancer incidence and mortality after treatment with folic acid and vitamin B12.

Department of Heart Disease, Haukeland University Hospital, Jonas Liesvei 65, Bergen, Norway 5021.
JAMA The Journal of the American Medical Association (Impact Factor: 29.98). 11/2009; 302(19):2119-26. DOI: 10.1001/jama.2009.1622
Source: PubMed

ABSTRACT Recently, concern has been raised about the safety of folic acid, particularly in relation to cancer risk.
To evaluate effects of treatment with B vitamins on cancer outcomes and all-cause mortality in 2 randomized controlled trials.
Combined analysis and extended follow-up of participants from 2 randomized, double-blind, placebo-controlled clinical trials (Norwegian Vitamin Trial and Western Norway B Vitamin Intervention Trial). A total of 6837 patients with ischemic heart disease were treated with B vitamins or placebo between 1998 and 2005, and were followed up through December 31, 2007.
Oral treatment with folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) and vitamin B(6) (40 mg/d) (n = 1708); folic acid (0.8 mg/d) plus vitamin B(12) (0.4 mg/d) (n = 1703); vitamin B(6) alone (40 mg/d) (n = 1705); or placebo (n = 1721).
Cancer incidence, cancer mortality, and all-cause mortality.
During study treatment, median serum folate concentration increased more than 6-fold among participants given folic acid. After a median 39 months of treatment and an additional 38 months of posttrial observational follow-up, 341 participants (10.0%) who received folic acid plus vitamin B(12) vs 288 participants (8.4%) who did not receive such treatment were diagnosed with cancer (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.03-1.41; P = .02). A total of 136 (4.0%) who received folic acid plus vitamin B(12) vs 100 (2.9%) who did not receive such treatment died from cancer (HR, 1.38; 95% CI, 1.07-1.79; P = .01). A total of 548 patients (16.1%) who received folic acid plus vitamin B(12) vs 473 (13.8%) who did not receive such treatment died from any cause (HR, 1.18; 95% CI, 1.04-1.33; P = .01). Results were mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B(12). Vitamin B(6) treatment was not associated with any significant effects.
Treatment with folic acid plus vitamin B(12) was associated with increased cancer outcomes and all-cause mortality in patients with ischemic heart disease in Norway, where there is no folic acid fortification of foods.
clinicaltrials.gov Identifier: NCT00671346.

Full-text

Available from: Per M Ueland, Apr 01, 2015
0 Bookmarks
 · 
163 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: In phenylketonuria (PKU), phenylalanine-free L-amino acid supplements are the major source of dietary micronutrients. Methods: Four hundred fifty-two retrospective annual/bi-annual non-fasting blood samples for nutritional markers (plasma zinc, selenium, and serum folate) from 78 subjects aged 1-16 years (median number of blood samples: 6, range 1-14) were analysed over 12 years. Longitudinal blood result data were available for 51 subjects (65%). The dietary intake from supplements was calculated. Results: The median intakes of all of the micronutrients studied were >200% of the reference nutrient intakes (RNI). There was no statistical correlation between dietary intake and nutritional markers outside of the normal reference range (RR) except for selenium, but there was a correlation between a lower plasma zinc, plasma selenium and haemoglobin status and better blood phenylalanine control in 1- to 4-year-old children. On at least one occasion, the individual plasma concentrations of zinc (71%, n = 54/76) and selenium (21%, n = 16/75) were below the RR; however, the concentrations of selenium (41%, n = 31/75) and serum folate (83%, n = 34/41) were also above the RR. Dietary intakes exceeded the upper tolerable intakes for zinc and copper (32%, n = 25) and folate (65%, n = 51). Individual longitudinal data demonstrated little change in micronutrient status over time. Conclusions: In PKU, biochemical micronutrient deficiencies are common despite micronutrient intakes above the RNI. Further study of the nutritional profiling of L-amino acid supplements in PKU is needed. © 2014 S. Karger AG, Basel.
    Annals of Nutrition and Metabolism 09/2014; 65(1):42-48. DOI:10.1159/000363391 · 2.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper is mainly to investigate the stability of synthetic folic acid under different conditions, including pH, temperature, light, and the presence of antioxidants. The results show that folic acid gives a good stability in the buffer of pH 8.05~10.40, whose reservation ratio can reach more than 93.1% in 72 h, while the preservation ratio of folic acid reduce to 23% in the buffer of pH1.95~6.40. Moreover, folic acid has a good stability in the buffer of pH 5.39~10.40, after water bath at 100°C for 2 h. Folic acid exhibits a good stability under the condition of weak illumination intensity. Increasing illumination intensity promotes a decrease in FA concentration. The combination of antioxidants Vitamin C (VC) and sodium citrate displays a significant effect on protecting folic acid from oxidation.
    09/2013; 781-784:1215-1218. DOI:10.4028/www.scientific.net/AMR.781-784.1215
  • [Show abstract] [Hide abstract]
    ABSTRACT: Clinical trials of chemoprevention for lung cancer have yielded negative results, with suggested worsening of cancer incidence in those who continue to smoke. Continued smoking over age 55 is associated with decreased longevity and multiple comorbidities. It is possible that clinical trials focusing on former smokers in both prevention and screening trials will yield significant benefit, now masked by the population of continued smokers.
    Clinical Lung Cancer 10/2014; 16(1). DOI:10.1016/j.cllc.2014.09.009 · 2.04 Impact Factor